Mouse Anti-VEGF Recombinant Antibody (clone A4.6.1) (CAT#: PABW-130)

Figure 1 In vivo potency and efficacy of anti-VEGF antibodies in inhibiting HM-7 (human colorectal) xenografts.

A, dose-responsive inhibition of tumor growth by A4.6.1, Y0317, B20-4.1, and G6-31 (5, 0.5, and 0.1 mg/kg, twice weekly) in HM-7 bearing mouse was shown by the tumor size (mm³) as a function of time (days). Error bars represent the S.E. (n = 10).

Liang, W. C., Wu, X., Peale, F. V., Lee, C. V., Meng, Y. G., Gutierrez, J., ... & Fuh, G. (2006). Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. Journal of Biological Chemistry, 281(2), 951-961.

Figure 2 Examination of tumor sections.

B, medium magnification images (bar = 500 μm) of pancreatic HPAC (a, e, and i) and colonic HM-7 (b, f, and j) xenografts treated with control antibody (a and b), anti-human VEGF, Avastin (A4.6.1 for HM-7) (e and f), or anti-mouse/human VEGF, G6-31 (i and j). All images are centered 1 mm from the tumor/host margin. High magnification images (bar = 50 μm) of HPAC (c, g, and k) and HM-7 (d, h, and l) tumor xenografts treated with control antibody (c and d), anti-human VEGF, Avastin (g and h), or anti-mouse/human VEGF, G6-31 (k and l). Compared with HM-7, HPAC xenografts are relatively stromarich (compare c and d). Control antibody-treated HPAC tumors have extensive stromal cells infiltration (arrowheads, c), with indistinct small-caliber vessels surrounded by connective tissue cells and matrix. Treatment of these tumors with anti-human (g) or anti-mouse/human VEGF (k) results in little change in tumor-stroma proportion. In contrast, control HM-7 tumors (d) have relatively sparse stroma, and large caliber thin walled vessels (arrow). Treatment with anti-human VEGF (h) reduces vessel diameter and increases the relative amount of stromal matrix and cells around remaining vessels. Similar but more dramatic changes occur when HM-7 tumors are treated with anti-mouse/human VEGF, G6-31 (l). Images c, d, g, h, and k are centered 1 mm from the tumor/host margin (left in the images); image l is centered 200 μm from the tumor/host margin (in this sample, only necrotic tumor is present at 1 mm from the host margin).

Liang, W. C., Wu, X., Peale, F. V., Lee, C. V., Meng, Y. G., Gutierrez, J., ... & Fuh, G. (2006). Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. Journal of Biological Chemistry, 281(2), 951-961.

Figure 1 Mouse Anti-VEGF Recombinant Antibody (PABW-130) in WB

Western blot analysis was performed with 0.1 µg (lane 1), 0.3 µg(lane 2), and 0.6 µg (lane 3) recombinant human VEGF onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least 1 hour. Membranes were probed with PABW-130 at 2ng/μL overnight at 4°C on a rocking platform. Then probed with Goat anti-Mouse IgG HRP secondary antibody at a dilution of 1:3,000 for one hour. Chemiluminescent was detected.

Figure 2 Mouse Anti-VEGF Recombinant Antibody (PABW-130) in Dot Blot

Dot Blot analysis of PABW-130 was performed by coating with human VEGF antigen.
PABW-130 incubation concentration: 2 ng/μL.
The secondary antibody: HRP-Anti-Mouse IgG (H+L)

Figure 3 Mouse Anti-VEGF Recombinant Antibody (PABW-130) in ELISA

ELISA analysis of PABW-130 was performed by coating with recombinant human VEGF antigen. Then blocked with BSA, and incubated with PABW-130 at a starting concentration of 2.5 µg/mL. The HRP-conjugated Goat anti-Mouse IgG as a secondary antibody. Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.